The efficacy of intradermal injection of type A botulinum toxin for facial rejuvenation

Dermatol Ther. 2017 Jan;30(1). doi: 10.1111/dth.12433. Epub 2016 Nov 12.

Abstract

The aim of this study is to evaluate the efficacy for effectiveness of type A botulinum toxin intradermal injection for facial rejuvenation. Forty female subjects were randomly divided into two groups: BoNTA group and control group. In BoNTA group, each subject's facial skin was treated with intradermal injection of BoNTA, and subjects of the control group were treated with intradermal saline solution injection. Subjects receiving one session of treatment and evaluations were conducted at baseline, four weeks, and twelve weeks after treatment. The outcome assessments included subjective satisfaction scale; blinded clinical assessment; and the biophysical parameters of roughness, elasticity, skin hydration, transepidermal water loss (TEWL), erythema, and melanin index. BoNTA group showed higher physician's global assessment score, subject satisfaction score, roughness, skin hydration, skin elasticity, and lower TEWL compared to that of control group at 12 weeks post-treatment. No significant difference was found among erythema and melanin index at baseline, four, and twelve weeks after treatment among the two major groups. In conclusion, intradermal BoNTA injection can be considered as an effective method for facial rejuvenation.

Keywords: BoNTA; facial rejuvenation; intradermal injection.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Acetylcholine Release Inhibitors / administration & dosage*
  • Acetylcholine Release Inhibitors / adverse effects
  • Adult
  • Aged
  • Botulinum Toxins, Type A / administration & dosage*
  • Botulinum Toxins, Type A / adverse effects
  • China
  • Cosmetic Techniques* / adverse effects
  • Female
  • Humans
  • Injections, Intradermal
  • Middle Aged
  • Patient Satisfaction
  • Photography
  • Rejuvenation*
  • Skin Aging*
  • Time Factors
  • Treatment Outcome

Substances

  • Acetylcholine Release Inhibitors
  • Botulinum Toxins, Type A